Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AES 2022 | How will the role of cenobamate evolve in the epilepsy space?

William E. Rosenfeld, MD, The Comprehensive Epilepsy Care Center for Children and Adults, St Louis, MO, shares his thoughts on how the role of cenobamate in the epilepsy treatment paradigm is likely to change in the coming years. Cenobamate is approved for the treatment of partial-onset seizures in adult patients, after two randomized, placebo-controlled trials demonstrated high proportions of patients achieving ≥50% and 100% reduction in seizure frequency. In these trials, cenobamate was given as an adjunctive therapy. With accumulating evidence demonstrating maintained seizure control and reductions in concomitant antiseizure medication drug load with cenobamate use, Dr Rosenfeld feels that an increasing number of patients will transition to cenobamate monotherapy. It may also move up in the treatment armamentarium as its use becomes more familiar. Dr Rosenfeld also highlights data demonstrating the efficacy of cenobamate in patients who do not have seizure control following epilepsy surgery, suggesting that it should be one of the agents considered prior to surgical intervention. This interview took place at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, TN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultant/advisor: Arvelle, SK Life Science, Inc.; Speaker: SK Life Science, Inc.; Research Support: SK Life Science, Inc., UCB Pharma.